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This briefing describes genetic healthcare services and public health screening programmes in 
Scotland. It includes a brief introduction to genetics in relation to healthcare; information on the 
four regional genetics services and an overview of recent developments in genetic healthcare in 
Scotland. This briefing also outlines public health screening programmes relating to pregnancy, 
newborn and adult screening. 
 
 2 
CONTENTS 
EXECUTIVE SUMMARY .............................................................................................................................................. 3 
INTRODUCTION .......................................................................................................................................................... 5 
POLICY CONTEXT .................................................................................................................................................. 5 
GENETICS SERVICES ................................................................................................................................................ 6 
WHAT ARE GENETICS SERVICES ....................................................................................................................... 6 
Clinical Genetics ................................................................................................................................................ 6 
Molecular Genetics and Cytogenetic laboratories ......................................................................................... 6 
Biochemical Genetics ........................................................................................................................................ 7 
GENETIC TESTING ................................................................................................................................................. 7 
GENETICS SERVICES IN SCOTLAND .................................................................................................................. 8 
National Services Division ................................................................................................................................ 8 
Workforce ........................................................................................................................................................... 8 
Budgets ............................................................................................................................................................. 10 
Research Funding ............................................................................................................................................ 10 
Calman Review ................................................................................................................................................. 11 
GENETICS ORGANISATIONS .............................................................................................................................. 12 
Scottish Genetics Education Network (ScotGEN) ........................................................................................ 12 
Scottish Genetic Alliance UK .......................................................................................................................... 12 
Gengage ............................................................................................................................................................ 12 
Generation Scotland ........................................................................................................................................ 13 
PUBLIC HEALTH SCREENING ................................................................................................................................ 13 
CRITERIA FOR A SCREENING PROGRAMME .................................................................................................. 15 
SCREENING PROGRAMMES IN SCOTLAND ..................................................................................................... 17 
PREGNANCY SCREENING .................................................................................................................................. 17 
Sickle Cell and Thalassaemia Screening....................................................................................................... 17 
Infectious Diseases Screening ....................................................................................................................... 18 
Down Syndrome Screening ............................................................................................................................ 19 
Fetal Anomaly Screening ................................................................................................................................ 19 
Diagnostic Testing ........................................................................................................................................... 20 
Pre-implantation Genetic Diagnosis (PIGD) .................................................................................................. 20 
NEWBORN SCREENING ...................................................................................................................................... 20 
Newborn Blood Spot Test ............................................................................................................................... 20 
Newborn Hearing Screening ........................................................................................................................... 22 
Newborn Physical Examination ...................................................................................................................... 22 
ADULT SCREENING ............................................................................................................................................. 22 
Bowel Cancer Screening ................................................................................................................................. 22 
Breast Cancer Screening ................................................................................................................................ 23 
Cervical Cancer Screening ............................................................................................................................. 23 
Diabetic Retinopathy Screening ..................................................................................................................... 24 
Abdominal Aortic Aneurysm (AAA) Screening ............................................................................................. 24 
APPENDIX 1: PROFESSIONAL GENETICS ASSOCIATIONS ................................................................................ 25 
APPENDIX 2: KEY SUPPORT ORGANISATIONS FOR WOMEN WITH ‘HIGH RISK’ PREGNANCIES ............... 28 
APPENDIX 3: KEY SUPPORT ORGANISATIONS FOR NEWBORN SCREEN POSITIVES .................................. 29 
APPENDIX 4: KEY SUPPORT ORGANISATIONS FOR ADULT SCREEN POSITIVES ......................................... 30 
SOURCES .................................................................................................................................................................. 31 
RELATED BRIEFINGS .............................................................................................................................................. 36 
 
 3 
 
EXECUTIVE SUMMARY 
Genetics services 
Genetic conditions, like any other condition, affect one or more parts of the body. They can be 
inherited from previous generations and passed on to future generations. Genetic healthcare in 
Scotland is provided by NHS-funded regional genetic services. These regional genetic services 
are located in Aberdeen, Dundee, Edinburgh and Glasgow and provide a service to patients 
throughout Scotland. Not only do the regional genetic services provide a face-to-face service 
through the clinicians and genetic counsellors, they provide a laboratory service for analysing 
samples taken to test for genetic conditions. 
The 2006 „Review of Genetics in Relation to Healthcare in Scotland‟ (the Calman Review) made 
a number of recommendations on how the Scottish genetics service could be improved. It 
recommended an increase in clinical staff, improved public engagement and a consortium 
approach to the provision of genetic services. As a result of the Calman Review, Gengage was 
established by the Scottish Government in 2008 to increase public awareness of genetics and 
to promote dialogue and debate on issues relating to genetic healthcare.  
There is a vast amount of genetic healthcare research taking place in Scotland. For example, 
Generation Scotland is a collaboration between Scottish medical schools, research institutes 
and the NHS. Generation Scotland aims to identify the genetic basis of common complex 
disease and use ethically-approved family and population-based studies to understand more 
about genetic disease. The Chief Scientist Office of the Scottish Government also funds genetic 
research via the Experimental and Translational Medicine Research Committee and the NHS in 
Scotland funds a number of clinical research projects.  
Public health screening 
Public Health Screening is the process used to identify apparently healthy people who may be 
at an increased risk of a disease or condition. Some screening programmes have a genetic 
component.  There are three strands of screening programmes.  These are prenatal screening, 
newborn screening and adult screening.  Screening programmes have advantages and 
disadvantages and are regulated by the UK National Screening Committee.  There are a 
number of criteria which must be met in order for a screening programme to be implemented. 
These include factors around the condition, the screening test, the treatment and the screening 
programme.  Screening cannot provide a clear diagnosis of any condition, and instead the 
results are called „presumptive‟.  When screening identifies someone at „high-risk‟ of a condition, 
they will be referred for further diagnostic testing. 
Prenatal screening is offered to all pregnant women in Scotland and takes the form of a blood 
test or an ultrasound scan.  Conditions such as sickle cell disease, thalassaemia, Down 
syndrome, fetal anomalies and infectious diseases are tested routinely as part of pregnancy 
screening.  When screening identifies a pregnancy as „high-risk‟, the mother may be offered a 
diagnostic test such as an amniocentesis or chorionic villi sampling (CVS).  Diagnostic tests 
allow parents to make informed choices about their pregnancy; however, there is a small risk of 
miscarriage associated with both of these diagnostic procedures. 
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Parents of all newborn babies in Scotland are offered a blood-spot screening test for their child. 
This test takes a spot of blood by pricking the heel of the baby and can test for five rare, but 
serious, conditions including cystic fibrosis.  Early diagnosis of any of these five conditions can 
allow for early treatment of the disease. 
Newborn babies are also tested as part of the Newborn Hearing Screening Programme for 
hearing defects, and the test usually takes place before the baby leaves hospital.  Newborns are 
also routinely given a physical head to toe examination before they leave hospital. Although this 
is routinely carried out in Scotland, it is not a national screening programme like it is in England. 
Adults of certain age groups are offered regular screening for breast cancer (women aged 50-
70, every 3 years); bowel cancer (adults aged 50-74, every 2 years) and cervical cancer 
(women aged 20-60, every 3 years). Uptake of screening for breast cancer and cervical cancer 
is relatively high at 74.9% and 73.6% respectively, compared to bowel cancer which has a low 
uptake of 53.7%. Uptake of bowel cancer screening is higher in females than in males and is 
affected by social factors with the lowest rate of uptake being in the poorest areas.  
Breast cancer screening in 2011/12 detected over 1,700 cases of breast cancer in Scotland. 
Regular bowel screening is estimated to reduce the risk of dying from bowel cancer by 16%. 
Cervical screening is estimated to save around 5,000 lives in the UK each year and regular 
cervical screening is estimated to prevent 8 out of 10 cervical cancers developing in the first 
instance.  The human papillomavirus (HPV) vaccination was introduced in Scotland in 2008 to 
help combat cervical cancer. It is offered to school girls aged 12-13 years.  The HPV vaccination 
prevents some forms of cervical cancers from developing in the first instance; however, it does 
not protect against all cervical cancers and therefore regular screening is still important. 
Diabetic retinopathy screening programme is offered annually to everyone aged 12 and over 
with diabetes.  The screening test looks for retinopathy which is a condition that can cause 
severe damage to the eye and can result in blindness.  Early detection can allow for the 
retinopathy to be treated and can prevent any serious damage from occurring. Diabetic 
retinopathy is the biggest single cause of blindness and visual impairment in Scotland amongst 
people with working age.  The rising prevalence of diabetes in Scotland means that diabetes is 
likely to remain a major health and economic problem and this screening programme will help 
reduce the health and economic problems associated with retinopathy. 
In July 2012, the Scottish Government announced its intention to roll out an abdominal aortic 
aneurysm (AAA) screening programme to all men entering their 65th year.  An AAA is an 
enlarged part of the aorta in the abdomen that has no symptoms unless it bursts, in which case 
it usually leads to death. AAA screening will only be offered to men aged 65 as 95% of AAA 
ruptures occur within this group.  This new screening programme, to be rolled out across the 
country by December 2013, is expected to prevent around 170 deaths each year and to shift the 
balance of care from reactive emergency treatment to preventative management through early 
diagnosis.  
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INTRODUCTION 
DNA (deoxyribonucleic acid) is the genetic code of life. It determines characteristics from eye 
colour and the ability/inability to tongue roll to predisposition to genetic (or inheritable) 
conditions. With the exception of identical twins, everyone has a unique DNA sequence. A gene 
is a short sequence of DNA. Humans each have around 25,000 genes. Genes are tightly 
packaged into little bundles known as chromosomes. There are 46 chromosomes in the nucleus 
(control centre) of each cell (23 inherited from the mother and 23 from the father). Cells are the 
basic building blocks of life and are like tiny bricks that make up the human body. 
Figure 1: DNA is packaged into chromosomes of which there are 23 chromosome pairs in each 
cell. Image used with kind permission of Genetic Alliance UK. 
 
A genetic condition can arise when there is a change in the DNA code of a particular gene or 
where there is a change to the structure of chromosomes. Genetic conditions, like any other 
condition, affect one or more parts of the body. They are, however, unique in that the condition 
can be inherited from previous generations and passed on to future generations.  
POLICY CONTEXT 
Provision of Healthcare Services in Scotland, including the provision of Genetic Healthcare 
Services, is devolved to the Scottish Parliament. However, ethical and legal matters relating to 
genetics are reserved to Westminster. Reserved matters include regulation of: 
 Genetic research 
 Genetic testing 
 Assisted conception (e.g. IVF, sperm/egg donation and surrogacy) 
 Xenotransplantation (transplantation of cells or organs from one species to another) 
 Embryology and 
 Abortion 
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The Emerging Science and Bioethics Advisory Committee (ESBAC) is responsible for providing 
advice to the four UK Health Ministers on emerging scientific developments and their ethical, 
legal and economic implications. Its remit involves the field of human genetics. The newly-
established ESBAC has taken over the responsibilities of the former Human Genetics 
Commission (HGC) which was the former UK Government‟s advisor on new developments in 
human genetics. The HGC was disbanded in June 2012 following a UK Government review of 
Arm‟s Length Bodies. The HGC‟s role was to advise the government on social, ethical and legal 
issues arising from genetics.  
GENETICS SERVICES 
WHAT ARE GENETICS SERVICES 
Genetics services encompass clinical genetics, molecular genetics, cytogenetics and 
biochemical genetics.  
Clinical Genetics 
Clinical Genetics is the branch of genetics healthcare that directly deals with patients. It is 
generally an outpatient service and involves: 
 Taking a detailed pedigree (family tree) analysis of genetic conditions and providing 
clinical assessment by family history; 
 Deciding on further investigations and taking samples for genetic testing (molecular or 
cytogenetic testing);  
 Genetic counselling: bringing all the information together and communicating it in an 
understandable way to allow families to make informed choices and decisions. Providing 
information about genetic risk for patients and family members; 
 Discussions about options available to patients, including therapies, diagnostic testing, 
management plans and support groups;  
 Diagnosis of rare genetic conditions; 
 Co-ordination of screening for specific rare syndromes; 
 Multidisciplinary working to direct investigation and management of specific diseases with 
significant genetic component. 
Molecular Genetic and Cytogenetic laboratories 
Molecular Genetic laboratories (or „DNA labs‟) provide a genetic testing facility for genetic 
conditions that arise from specific changes (mutations) in the DNA code. For example, some 
inheritable breast cancers can result from changes in one of two specific genes: BRCA1 and 
BRCA2. 
Cytogenetic laboratories (or „chromosome labs‟) provide a genetic testing facility for genetic 
conditions that arise from chromosomal abnormalities. For example, Down syndrome is caused 
by 3 copies of chromosome 21 (an individual normally would have only two copies of each 
chromosome – one maternal and one paternal).  
 
 7 
Biochemical Genetics 
Biochemical Genetics labs provide a genetic testing facility for genetic conditions for conditions 
that produce an unusual amount of protein in a blood sample. This includes testing prenatal 
screening samples for neural tube defects and Down syndrome. The Scottish Newborn 
Screening Laboratory is based at the Biochemical Genetics Department at the West of Scotland 
Regional Genetics Service (See Figure 2) and tests newborn babies for rare but serious genetic 
conditions.  
GENETIC TESTING 
A genetic test is a test that looks for specific changes to a particular gene that is known to cause 
a particular genetic condition. There are four types of genetic testing (ScotGEN, 2012): 
Diagnostic Genetic Test – this is undertaken because a diagnosis is suspected in a patient. 
Most of these tests can be requested directly by a doctor, although more complex cases might 
be referred to one of Scotland‟s regional genetic services. This includes diagnostic testing for 
suspected cancer cases. 
Predictive Genetic Test – this is undertaken for a patient who is well but has a family history of a 
particular genetic condition. For example, someone with a family history of Huntington‟s disease 
might be offered a predictive test to determine if they are going to develop the condition. 
Predictive genetic testing will only be authorised by a Clinical Geneticist or Genetics Counsellor. 
Carrier Test – this is undertaken for a patient who is well and will never develop the condition 
themselves, but may transmit the condition to their children. Testing for cystic fibrosis is an 
example. Carrier testing allows women (and partners) to make informed choices about existing 
or future pregnancies. 
Screening Test – this is offered to a particular group of people for a particular condition. An 
example is the screening offered to pregnant women for Down syndrome. Screening tests are 
discussed in more detail below (see page 10). 
The UK Genetic Testing Network (UKGTN) advises the NHS in all four UK countries about 
genetic testing for inheritable genetic conditions. It aims to ensure the provision of high quality 
genetic testing services. UKGTN is a network of genetic testing laboratories, clinicians and 
commissioners of NHS genetic services and involves input from patient groups (UKGTN, 
2012a). The UKGTN assess whether or not a genetic test is likely to be of benefit to patients. If 
it is, then a recommendation is passed to the Genetics Commissioning Advisory Group 
(GenCAG) who will then request that the relevant commissioners provide funding for the test. In 
Scotland, the National Services Division is responsible for commissioning genetic testing 
(UKGTN, 2012b). 
The Scottish Genetics Laboratory Consortium (which is funded by National Services Division) 
determines which genetic tests molecular genetics and cytogenetics laboratories perform. The 
consortium ensures that the Scotland‟s four regional genetics services work together to avoid 
duplication and to provide genetic testing for a wide range of conditions efficiently (National 
Services Division, 2012b). Tests for rare genetic conditions not available in Scotland are 
sourced from England or abroad (National Services Division, 2012b). The Scottish Genetics 
Laboratory Consortium has the role to: 
 Openly discuss and agree workload distribution between the four regional genetics 
services so as to make the most effective use of available resources; 
 8 
 Consider the classification and declassification of genetic tests by the UK Genetic 
Testing Network (UKGTN) so as to ensure that all tests undertaken are evidence based 
(National Services Division, 2012b). 
GENETICS SERVICES IN SCOTLAND 
Healthcare for patients affected by or at risk of a genetic condition is delivered by regional 
genetics services. In Scotland, there are four regional genetics services as shown in Figure 2. 
Figure 2: Scotland’s four Regional Genetics Services and their health board catchment 
areas 
 
National Services Division 
National Services Division is a division within NHS National Services Scotland (NSS). National 
Services Division receives top-sliced, ring-fenced funding from the Scottish Government to 
commission and performance-manage nationally designated specialist services, national 
managed clinical networks and screening programmes on behalf of NHS Scotland. The National 
Services Division is responsible for commissioning and performance-managing specialist 
services (including molecular genetic and cytogenetic laboratories) on behalf of NHS Scotland. 
National Services Division aims to: 
 Ensure equity of access for all Scottish residents to specialist and screening services; 
 Ensure the best possible clinical outcomes within the funding available; 
 Provide a secure funded environment for the establishment and development of new 
national services; 
 Provide a risk-sharing arrangement for NHS Boards where incidence is sporadic and 
treatment involves specialist skills or expensive equipment; and 
 Avoid the unnecessary proliferation of duplicate services, thus promoting clinical quality 
and cost effectiveness (National Services Division, 2012a). 
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Workforce 
Regional genetics services are staffed by a number of specialists in addition to the 
administrative, technical and support staff. The specialists are: 
Clinical Geneticists – these are medically qualified doctors who specialise in clinical genetics. 
Clinical Geneticists usually deal with more complex cases of inheritable genetic conditions. 
Genetic Counsellors – these are healthcare professionals usually with a science or nursing 
background. Genetic Counsellors can specialise in one or more types of Genetic Conditions. 
Genetic counsellors can register with the Genetic Counselling Registration Board (GCRB), 
although registration is currently voluntary. In Scotland, there are 26 Genetic Counsellors, 13 of 
whom are GCRB-registered (GCRB, 2012). The GCRB was established by the profession to 
regulate the standards of practice of Genetic Counsellors in the UK. Its purpose is to establish, 
maintain and improve standards of practice to assure public safety. Workforce levels for Genetic 
Counsellors at the four Regional Genetics Services are shown in Table 1. 
Table 1: Genetic Counsellor Workforce in Scotland 
Regional Genetics Service Number of Genetic Counsellors 
North of Scotland 6 
East of Scotland 4 
West of Scotland 10 
South East Scotland 6 
 
Genetic Counsellors with a scientific background require a GCRB-approved MSc in Genetic 
Counselling (in the UK these courses are only available at Manchester University and Cardiff 
University).  Genetic Counsellors with a nursing background are not required to have the MSc 
on appointment; however, there is the expectation that they will gain it at some point. In England 
& Wales, the Department of Health has set up Genetic Counsellor training posts; however, no 
such scheme has been implemented in Scotland. 
Clinical Scientists – these healthcare professionals provide the laboratory service for genetic 
testing.  Clinical Scientists in the regional genetics services usually specialise in either 
molecular genetics or cytogenetics. However, traineeships have recently been established in 
molecular pathology, which integrates both genetic specialities and incorporates analysis of 
cancerous tumours.  
Total staffing for the regional genetics laboratories in Scotland is approximately 155 whole time 
equivalents (WTE). The workforce is divided up as shown in Table 2 (National Services 
Division, 2012c), below. 
The head of a regional genetics service is usually a Consultant Clinical Scientist or Consultant 
Clinical Geneticist. There are a number of associations representing genetics healthcare 
professionals (Appendix 1). 
NHS Education for Scotland is the special health board responsible for delivering and 
developing education and training for those who work in NHS Scotland. NHS Education for 
Scotland covers national postgraduate pre-registration training for clinical scientists, support for 
other groups, leadership development across healthcare science, support staff initiatives and 
trainers and assessors (NHS Education for Scotland, 2012).  
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Table 2: Genetic Laboratories Workforce in Scotland 
Role WTE 
Consultant Clinical Scientist 29.0 
Principal Clinical Scientist 10.1 
Clinical Scientist 46.8 
Biomedical Scientist 3.6 
Biomedical Support 1.0 
Healthcare Scientist 0.5 
Healthcare Scientist Associate 2.0 
Healthcare Assistant 2.0 
Quality Manager 2.3 
Laboratory Manager 2.0 
Senior Genetic Technologist 9.5 
Genetic Technologist 27.3 
Medical Technical Officer 8.0 
Administrative 11.9 
Information Technology 0.2 
TOTAL 155 
Budgets 
As shown in Table 3, total public funding for molecular and cytogenetic laboratory services in 
Scotland across the four regional genetics services in 2011/12 was £10,725,388. This includes 
staffing, equipment, consumables and maintenance (National Services Division, 2012c). In 
addition, £464,574 was spent on tests that were sent to other laboratories outside Scotland 
(National Services Division, 2012c):  
Table 3: Molecular Genetic & Cytogenetic Laboratory Services Public Spending 
2011/12 
Spending 2011/12 £ million 
Total in Scotland 10.725 
Tests sent to labs outside Scotland 0.465 
Total Genetics Spending 11.190 
 
Research Funding 
There are a number of research centres in Scotland specialising in genetics research. For 
example, the Medical Research Council (MRC) Human Genetics Unit, based at the Southern 
General Hospital in Edinburgh, studies the genetic basis of disease. In August 2012, the MRC 
announced £60m of funding for Edinburgh University‟s Institute of Genetics and Molecular 
Medicine (IGGM) (BBC, 2012). This funding aims to help IGGM scientists gain insights into 
conditions such as cancer, arthritis and schizophrenia and could help the scientists develop new 
tests and therapies for patients (BBC, 2012). 
The Scottish Government Chief Scientist Office (CSO) has the responsibility for encouraging 
and supporting research into health and health care needs in Scotland. This includes research 
into genetics. Genetics research is a very broad field and the figures for research funding are 
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therefore interpretive. The CSO funds a number of genetics healthcare research projects. These 
include funding through the Experimental and Translational Medicine Research Committee 
(ETMRC). The ETMRC has an annual budget of £5.2m. The Scottish Government estimates 
that around 25% of the research projects funded through ETMRC have a genetics component 
(Scottish Government, 2012a).  In addition, the CSO funds Generation Scotland (discussed 
below). Funding over the past 5 years for this project is shown in Table 4 (Scottish Government, 
2012a). 
Table 4: Scottish Government Chief Scientist Office funding of Generation 
Scotland 
Year £ million 
2007 1.0 
2008 1.0 
2009 1.0 
2010 0.7 
2011 0.4 
 
The CSO also funds two Scottish Experimental Cancer Medicine Centres (ECMCs), one at 
Glasgow and a second ECMC which is a collaboration between Edinburgh and Dundee. 
ECMCs are set up to conduct early phase clinical trials, all of which have a genetic component 
to their research. Total funding to the Scottish ECMC‟s by the CSO from 2007-11 was £325K 
(Scottish Government, 2012a). The CSO also invests the majority of its annual budget in the 
infrastructure that allows NHS Scotland to participate in high impact clinical research. This could 
be labelled as genetics research. The CSO estimates of funding for clinical research is shown in 
Table 5 (Scottish Government, 2012a). 
Table 5: Scottish Government Chief Scientist Office estimated funding for Clinical 
Research 
Year £ million 
2007 2.6 
2008 2.6 
2009 2.6 
2010 2.3 
2011 2.0 
Calman Review 
In 2006, Professor Sir Kenneth Calman led the „Review of Genetics in Relation to Healthcare in 
Scotland‟ (Calman Review) (Scottish Government, 2006). The Calman Review made a number 
of recommendations about genetic healthcare in Scotland with regards to staffing, public 
engagement and clinical and laboratory services.  
The Calman Review resulted in significant funding being made available to upgrade clinical and 
laboratory facilities and recruit more medical, clinical, scientific, administrative and nursing staff 
within the regional genetics services. It led to further funding in genetic healthcare services and 
an increase in the number of Consultant Geneticists and Genetic Counsellors in Scotland. It 
also paved the way for a Neuromuscular Clinical Geneticist role with pan-Scotland 
responsibilities. The review also made funding available for specialist genetic care co-ordinators 
for complex single gene disorders. 
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The Calman Review also resulted in the extension of the consortium approach from molecular 
genetic to include cytogenetic services. As a result, the Scottish Genetics Laboratory 
Consortium was established to allow for sharing of resources and workforce across Scotland‟s 
four regional genetics services. The aim of this has been to achieve workflow balancing, 
resulting in lower reporting times.   
Public engagement in genetics is another area that was discussed in detail in the Calman 
Review. As a result of the review, Gengage (discussed below) was established as a formal 
funded network to link all of those with a background or interest in genetics with the general 
public.  
GENETICS ORGANISATIONS 
There are a number of professional associations for genetics healthcare specialists and clinical 
scientists. These associations usually have a UK-wide remit. For more information about these 
associations, see Appendix 1. In addition to these, there are a number of genetics organisations 
in Scotland. 
Scottish Genetics Education Network (ScotGEN) 
ScotGEN is funded by the Scottish Government, is a collaboration between Scotland‟s four 
regional genetics services and Scotland‟s universities. It is a network for people involved in the 
teaching of genetics for healthcare in Scotland and provides teaching materials.  
ScotGEN is also home to the Scottish Clinical Genetics Forum. This is a network between the 
four regional genetics services, National Services Division, Gengage, Scottish Genetic Alliance 
UK, the Scottish Government and other interested parties, including those from overlapping 
healthcare specialities and patient groups. The Scottish Clinical Genetics Forum aims to help 
develop an innovative, seamless service and integrate patient and public views into service 
planning and care guidelines (ScotGEN, 2012). It allows for the sharing of knowledge and 
expertise whilst setting a series of standards to measure staffing levels, waiting times, referrals 
and best clinical practice. The clinical genetics forum aims to agree quality standards and 
common ways of working across the regional genetics services. 
Scottish Genetic Alliance UK 
Scottish Genetic Alliance UK represents patients and families in Scotland to ensure that their 
voice is heard by decision makers such as NHS Scotland and the Scottish Government. They 
aim to improve the lives of people affected by genetic conditions by ensuring that high quality 
services are available to everyone who needs them. They aim to raise awareness of genetic 
conditions and campaign on policy issues. 
Gengage 
The Scottish Healthcare Public Engagement Network (Gengage) was established by the 
Scottish Government in 2008 following recommendations in the Calman Review, and its funding 
comes to an end in 2012. Its remit is to co-ordinate the efforts in Scotland to increase public 
awareness, dialogue and debate on issues to do with healthcare genetics. Gengage is funded 
by the Scottish Government and managed by the ESRC Genomics Policy and Research Forum 
at the University of Edinburgh. 
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Generation Scotland 
Generation Scotland is a collaboration between the four Scottish Medical Schools (Aberdeen, 
Dundee, Edinburgh & Glasgow), biomedical research institutes and NHS National Services 
Division. It aims to create ethically-sound family and population-based infrastructure to identify 
the genetic basis of common complex diseases. Current projects include the Scottish Family 
Health Study (GS:SFHS), Genetic Health in the 21st Century (GS:21CGH) and the Donor DNA 
Databank (GS:3D). So far, over 30,000 participants have been recruited to these three projects. 
PUBLIC HEALTH SCREENING 
Screening is the process of identifying apparently healthy people who may be at an increased 
risk of a disease or condition. People who are identified as being at increased risk of a disease 
or condition during screening can then be offered information, further tests and appropriate 
treatment to reduce their risk and/or any complications arising from the disease or condition. 
Screening is associated with some complex terminology and these are explained in Table 6. 
Table 6: Explanation of Screening Terminology 
Term Description 
Cut-off level Screening tests divide people into low-risk or high-risk groups. People 
in high-risk groups are offered further analysis. The cut-off point is the 
point defined by the programme to separate low-risk from high-risk 
Detection rate / 
Sensitivity 
A high detection rate or high sensitivity means that the test identifies 
as many people as possible with the condition. Detection rate / 
sensitivity is measured as the proportion of those with the condition, 
who have a positive (high-risk) screening result 
False-negative result People who have the condition being screened for but are given a 
negative (low-risk) result during screening 
False-positive result People who do not have the condition being screened for but are 
given a positive (high risk) result during screening 
High-risk People who are given a positive screening result 
Low-risk People who are given a negative screening result 
Negative predictive 
value 
The proportion of people with a negative (low risk) screening result 
who actually do not have the condition being screened for 
Positive predictive 
value 
The proportion of people with a positive (high-risk) screening result 
who actually do have the condition 
Presumptive result Screening tests divide people into high-risk and low-risk categories. 
They do not provide a definite answer. Screening results are called 
presumptive results until they are confirmed by diagnostic tests 
Prevalence The number of individuals in a population with the target condition 
Screening Testing people who do not have signs or symptoms of the condition 
being tested for with the aim of reducing risk of an adverse outcome 
or giving information about risk 
Specificity High specificity means the test has as few false positives as possible. 
It is measured as the proportion of those without the condition who 
have a negative result 
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Target condition The condition that the screening programme is aiming to find, to 
reduce the risk of adverse effects from that condition 
Target population The target group who are offered screening 
True-negative result People who are given a negative (low-risk) screening result who do 
not have the condition being screened for 
True-positive result People who are given a positive (high-risk) screening result who do 
have the condition being screened for 
Uptake The proportion of people, who when offered a test, take it up 
 
The easiest way to understand the screening process is to think of it as a kitchen sieve 
(National Screening Committee, 2012a). Screening programmes aim to identify individuals with 
or at risk of a particular condition or disease. This is known as the target condition. Screening 
programmes also have a target population. This is the group of people that the programme aims 
to screen. The target population are offered screening and those that uptake the invitation for 
screening are asked to “pass through the sieve”. Passing through the sieve is a metaphor for 
taking a screening test, such as having an ultrasound scan or giving a blood sample for 
laboratory analysis. In an ideal screening programme, the people without the target condition 
will pass through the sieve. People who pass through the sieve are deemed „low-risk‟ and are 
not referred for further testing. These people are called true-negatives because the screening 
programme has classified them as „low-risk‟ and they do not have the target condition.  The 
people who do not pass through the sieve who do have the condition are called true-positives. 
They have been identified as „high-risk‟ by the screening programme and further testing has 
confirmed that they do have the target condition. 
However, the screening process is not that simple and there are some problems with the sieve 
model. Sometimes, people who do have the target condition can pass through the sieve. They 
are false-negatives because they have been given a „low-risk‟ result by screening but they do 
actually have the target condition. Similarly, those who do not pass through the sieve who do 
not have the target condition are false-positives because they have been deemed „high-risk‟ by 
the screening programme but further tests have shown that they do not have the target 
condition.  
The results given by screening are called „presumptive‟ results because screening does not 
provide a clear diagnostic result. Screening only categorises individuals into „high-risk‟ or „low-
risk‟ categories. A „cut-off‟ point is defined that separates low-risk results from high-risk results. 
The cut-off point is based on scientific evidence of likelihood that an individual above or below 
this point will have the target condition. 
There are two main performance indicators for screening tests. The detection rate (or 
sensitivity) of a screening programme is the measure of all those with the target condition in the 
target population that screening identifies as „high-risk‟. Specificity of a screening programme 
refers to the proportion of individuals without the target condition that are classified as low-risk 
by the screening programme. Screening programmes are therefore continuously monitored and 
reviewed by the National Screening Committee to ensure that the screening programme is 
effective. 
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CRITERIA FOR A SCREENING PROGRAMME 
The UK National Screening Committee, currently chaired by Scotland‟s Chief Medical Officer, 
Sir Harry Burns, advises the NHS and Health Ministers throughout all four UK countries about 
all aspects of screening and supports the implementation of screening programmes. The role of 
the National Screening Committee is to provide expert independent policy advice on what 
screening programmes to implement based on quality research.  
Screening programmes have limitations and important practical and ethical differences from 
clinical practice as screening targets apparently healthy people. The potential harms of 
screening must be weighed up against the benefits. Screening aims to help them make better 
informed choices about their health. Screening can allow for early diagnosis of conditions and 
can therefore allow people to make informed choices or begin treatment early. The National 
Screening Committee aim to only implement screening programmes that do more good than 
harm. The criteria for a screening programme is detailed in Box 1.  
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Box 1: Criteria for a Screening Programme (National Screening Committee, 2012b). 
The Condition 
 The condition should be an important health problem and its epidemiology and natural 
history should be adequately understood 
 There should be a detectable risk factor, disease marker or early symptomatic stage 
 All cost-effective reasonable primary interventions must have been implemented 
 If carriers of a mutation are identified during screening, the consequences should be 
understood including psychological implications 
The Test 
 The screening test should be simple, safe, precise and validated 
 The test should be acceptable to the population 
 The distribution of test values in the target population should be known and a suitable 
cut-off level defined and agreed 
 There should be an agreed policy on the further diagnostic investigation of individuals 
with a positive test result and on the choices available to those individuals 
 If the test is for mutations, the criteria used to select the mutations to be covered by 
screening, if all possible mutations are not being tested, should be clearly set out 
The Treatment 
 There should be an effective treatment for those affected by the treatment 
 There should be evidence that early intervention will lead to better outcomes 
 There should be agreed evidence-based policies covering which individuals should be 
offered treatment and the appropriate treatment to be offered 
 Clinical management of the condition and patient outcomes should be optimised in all 
health care providers prior to participation in a screening programme 
The Screening Programme 
 The complete screening programme (test, diagnostic test, treatment) is clinically, 
socially and ethically acceptable to health professionals and the public 
 There should be evidence from control trials that the screening programme is 
effective in reducing mortality or morbidity. Where screening is aimed at providing 
information to allow the person being screened to make an informed choice (e.g. 
Down syndrome screening), there must be evidence from trials that test accurately 
measures risk.  
 The information that is provided about the test and its outcome must be of value and 
readily understood by the individual being screened 
 The benefits of the programme should outweigh the physical and psychological harm  
 The cost of the entire programme should be economically balanced in relation to 
health care spending as a whole. It should offer value for money.  
 All other options should have been considered to ensure that no more cost effective 
intervention could be introduced 
 There should be a plan for managing and monitoring the screening programme and 
an agreed set of quality assurance standards 
 Adequate staffing and facilities should be available prior to the programme starting 
 Information explaining the consequences of testing, investigation and treatment 
should be available to potential participants to allow them to make an informed choice 
 Public pressure for widening the eligibility criteria & reducing the screening interval 
and for increasing sensitivity of the testing process should be anticipated. Decisions 
about these parameters should be scientifically justifiable to the public 
 If screening is for a mutation, the programme should be acceptable to people 
identified as carriers and to other family members 
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SCREENING PROGRAMMES IN SCOTLAND 
In Scotland, there are 3 streams of public health screening programmes: pregnancy screening, 
newborn screening and adult screening (Figure 3). 
Figure 3: Public Health Screening Programmes in Scotland 
 
PREGNANCY SCREENING 
There are several national screening programmes available to pregnant women (Figure 3). 
These are routinely explained, discussed and performed by a midwife or a doctor.  In some 
more complicated cases where there is a family history of a genetic disorder, the woman might 
be invited for genetic counselling.  
Sickle Cell and Thalassaemia Screening 
Pregnant women are offered a blood test within the first 10 weeks of pregnancy to screen for 
sickle cell disorder (SCD) and thalassaemia disorders. SCD affects the shape of red blood cells 
(the cells which carry Oxygen around the body). The change in shape means that the cells get 
stuck in small blood vessels and can cause great pain and damage to the baby‟s body. It can 
sometimes be fatal. Once detected though, antibiotics and immunisations can help prevent 
serious illness. Thalassaemia disorders are a group of genetic disorders that affect the body‟s 
ability to create new red blood cells. Since red blood cells are needed to carry Oxygen around 
the body, people with certain types of thalassaemia are very anaemic. They need regular blood 
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transfusions (every 4-6 weeks) and need injections and medicines for the rest of their lives 
(NHS Choices, 2012a). 
Babies can only inherit a thalassaemia disorder if they inherit the altered form of the gene from 
both parents. Both parents need to be „carriers‟ of the disease i.e. have one copy of the normal 
gene and one copy of the altered gene. Anyone can be a healthy carrier. It is only when two 
copies of the altered gene are inherited that it becomes problematic. People are more likely to 
be „carriers‟ of an altered thalassaemia gene if they are from South Asia, East Asia, the Middle 
East, South America or the Mediterranean. This is because being a „carrier‟ in these countries is 
common as it helps protect against malaria (NHS Choices, 2012a). Polish people also have a 
high carrier frequency as many people who migrated to Poland many generations ago were 
from places where malaria was common. Some NHS boards take a family history survey to see 
if the baby is likely to be at risk of a sickle cell or thalassaemia disorder. 
If the baby is found to be at high risk of SCD or thalassaemia, a diagnostic test (amniocentesis 
or chorionic villi sampling) can be offered to provide a conclusive diagnosis. This is intended to 
provide the parents with the information to allow them to make informed choices about the 
pregnancy. 
Infectious Diseases Screening 
Screening for infectious diseases during pregnancy is routinely offered as a blood test at 8-12 
weeks. The infectious diseases screened for are described in Table 7. 
Table 7: Infectious Diseases Pregnancy Screening (National Services Division, 2012d). 
Infectious 
Disease 
Description 
Rubella Rubella is generally a mild illness. Most people are immunised against rubella 
infection during childhood. However, some people have not been immunised 
and if they are infected with rubella during the first 20 weeks of pregnancy, it 
can lead to deafness in the baby. Early detection and simple treatment can 
reduce risks to both mother and baby. 
Hepatitis B Hepatitis B is a virus that affects the liver and can be carried in the blood for 
many years without any signs or symptoms. Hepatitis B infection can be 
passed from mother to baby at birth. Early detection can prevent babies being 
infected with the virus which can prevent serious liver disease in adulthood. 
Syphilis Syphilis is a rare sexually transmitted infection that can damage the health of 
the baby. Early detection during pregnancy can be treated quickly and simply 
using antibiotics. 
HIV HIV is the virus that can lead to AIDS. HIV damages the immune system and 
destroys the body‟s defences against infection and disease. Infected mothers 
can pass the virus to their babies during pregnancy, birth or via breastfeeding. 
Women identified as HIV+ during pregnancy will be referred for specialist 
treatment & medication that can reduce the chance of HIV being passed to the 
baby. 
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Down Syndrome Screening 
Down syndrome is a genetic disorder that is characterised by an extra copy (i.e. 3 copies) of 
chromosome 21. It is characterised by learning disabilities and distinct physical features. 
However, people with Down syndrome, like everyone else, vary a lot in appearance, personality 
and ability. The severity of the condition will also vary from individual to individual. 
Down syndrome can occur in pregnancies of women of any age. However, the older the mother 
is during pregnancy, the higher likelihood she has of having a child with Down syndrome. For 
example, a pregnant woman aged 22 has a 1:1450 chance of having a baby with Down 
syndrome whereas a pregnant 45 year old woman has a 1:45 chance (Barts and The London 
Medical School, 2012). Down syndrome can also be inherited in a way that all children of a 
couple will be affected, however this is extremely rare.  
During pregnancy, a blood test at 11-14 weeks is routinely taken to look at levels of different 
proteins in the blood. Levels outside the „normal‟ range can indicate a positive screening result 
for Down syndrome. A second screen for Down syndrome during pregnancy is the nuchal 
translucency ultrasound scan (early pregnancy ultrasound scan). This scan measures the 
amount of fluid at the back of the baby‟s neck and is then analysed by a computer programme. 
A higher nuchal translucency measurement indicates a positive result for the screening and 
these pregnancies are deemed high-risk. The early pregnancy ultrasound scan can also detect 
genetic conditions such as Edwards syndrome1 and Patau syndrome2; unfortunately however, 
most Edwards & Patau pregnancies will result in miscarriage. 
Pregnant women identified as high risk during screening for Down syndrome will be offered 
information about Down syndrome and a diagnostic test (see below). If a diagnostic test 
confirms Down syndrome, the women (and partner) will be able to discuss their options with 
their midwife. They may also be advised to contact Down Syndrome Scotland, a support group 
for everyone affected by the condition and for new parents of a Down syndrome child.  
Fetal Anomaly Screening 
The mid-pregnancy ultrasound scan for fetal anomalies takes place between 18-21 weeks. The 
aim of fetal anomaly ultrasound screening is to identify: 
 Anomalies that are not compatible with life; 
 Anomalies associated with high morbidity and long-term disability; 
 Fetal conditions with the potential for intrauterine therapy; and 
 Fetal conditions that will require postnatal investigation or treatment (National Screening 
Committee, 2005). 
Fetal anomaly screening can detect abnormalities including cleft lip, Patau syndrome, Edward‟s 
syndrome, lethal skeletal dysplasia, open spina bifida and ancephalies (NHS Scotland, 2010). 
Screening has been found to detect 44.7% of all fetal anomalies, although detection rates vary 
for different anomalies (NHS National Screening Committee, 2005). 
                                            
1
 Edwards syndrome (Trisomy 18) is caused by an extra copy of chromosome 18 (like Down syndrome which is 
caused by an extra copy of chromosome 21). It usually results in miscarriage. In cases where live birth is given to a 
baby, the baby will suffer from severe internal organ problems and the average life expectancy is 2 months 
(Patient.co.uk, 2011a). 
2
 Patau syndrome (Trisomy 13) is caused by an extra copy of chromosome 13. It usually results in miscarriage. In 
cases where live birth is given to a Patau syndrome baby, the baby is likely to suffer severe physical abnormality 
and the median survival rate is 2.5 days (Patient.co.uk, 2011b). 
 20 
Diagnostic Testing 
Those identified during screening as being at „high risk‟ can be offered a diagnostic test to 
confirm if the unborn baby could develop, or has developed an abnormality or serious health 
condition. Diagnostic testing can be either by amniocentesis or chorionic villi sampling (CVS). 
These procedures are summarised in Table 8. 
Table 8: Comparison of Amniocentesis and CVS as prenatal diagnostic procedures 
 Amniocentesis Chorionic Villi Sampling 
(CVS) 
The procedure A needle is injected into the 
womb to take a sample of 
amniotic fluid (fluid that 
surrounds the fetus) 
A sample of chorionic villi cells 
are taken from the woman‟s 
placenta for analysis 
Miscarriage rate as a direct 
result of the procedure 
1 in 100 1 in 50 
Time at which procedure 
can be carried out 
15-16 weeks of pregnancy 10-14 weeks of pregnancy 
 
Although CVS carries a higher risk of miscarriage than amniocentesis, CVS can be performed 
earlier, which would result in a less traumatic termination of pregnancy should a woman (and 
partner) opt to terminate the pregnancy. The midwife, genetic counsellor or other health 
professionals will discuss the advantages and disadvantages of both diagnostic procedures with 
women (and partners) of high-risk pregnancies, should they decide to have a diagnostic 
procedure. 
Pre-implantation Genetic Diagnosis (PIGD)  
PIGD is an option for couples who are both carriers of a sickle cell disorder, but do not want to 
pass this disorder onto their baby. It is similar to in vitro fertilisation (IVF). IVF is a method that 
helps infertile couples conceive by removing an egg from the woman‟s ovaries and fertilising it 
with a man‟s sperm in a laboratory. Similarly, PIGD removes eggs from a woman‟s ovaries and 
these are fertilised with her partner‟s sperm. The fertilised embryo is then tested for sickle cell 
disorder and if the results are negative, the embryo is then implanted into the woman‟s womb. 
There is no guarantee that PIGD will be successful as there is only a 1 in 5 success rate (NHS 
Choices, 2012b). In most cases, PIGD is only carried out by private clinics and would cost 
around £8000 for a course of treatment (NHS Choices, 2012b). 
NEWBORN SCREENING 
Two screening programmes exist for newborn babies in Scotland. These are the newborn blood 
spot test and the universal newborn hearing screening programme.  
Newborn Blood Spot Test 
National Services Division is responsible for monitoring and evaluating newborn blood spot 
screening for all newborn babies (formerly known as the „Guthrie test‟). National Services 
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Division has commissioned the Biochemical Genetics Department at the West of Scotland 
Regional Genetics Service (Southern General Hospital, Glasgow) to operate the Scottish 
Newborn Screening Laboratory. Its remit is: 
 To screen blood samples of all babies born in Scotland (currently around 60,000 per 
year); 
 To ensure the reporting of all results to the proper authorities and the prompt referral of 
all positive cases for treatment; 
 To provide data on incidence of the conditions as required; and 
 To review new technology with a view to the incorporation of new tests/methods into the 
screening programme. (National Services Division, 2012e). 
This test identifies babies who may have rare but serious conditions. Early treatment can 
improve health and prevent severe disability or death. The blood spot test is offered to all 
newborn babies in Scotland and tests for the genetic conditions set out in Table 9. The test is 
usually performed by a midwife who will prick the baby‟s heel to obtain a few drops of blood that 
is then sent to the Scottish Newborn Screening Laboratory for analysis.  
Table 9: Genetic conditions tested in newborn blood spot test (National Services 
Division, 2012e) 
Genetic condition Incidence for 
babies born in 
Scotland 
Features 
Phenylketonuria 
(PKU) 
1 in 8000  PKU is a rare genetic disorder whereby the baby 
cannot digest phenylalanine (which is found in 
most foods). PKU can be treated with a very strict 
diet that is low in phenylalanine. 
Cystic Fibrosis (CF) 1 in 2500  Around 1 in 25 people in Scotland have the altered 
version of the CF gene. CF occurs when a baby 
inherits altered copies of the CF genes from both 
parents. It affects the lungs the most and causes 
chest infections and problems digesting food. 
Sickle Cell Disorder 
(SCD) 
1 in 2500  SCD affects the shape of red blood cells (the cells 
which carry Oxygen around the body). The change 
in shape means that the cells get stuck in small 
blood vessels and can cause great pain and 
damage to the baby‟s body. It can sometimes be 
fatal. However, once detected, antibiotics and 
immunisations can help prevent serious illness.  
Congenital 
Hyperthyroidism 
(CHT) 
1 in 3500  CHT means that the baby can‟t produce enough of 
the thyroxine hormone. This hormone is needed 
for mental and physical development. Early 
detection means the baby can be treated with 
throxine medicine. 
Medium Chain 
Acetyl-CoA 
Dehydrogenase 
Deficiency (MCADD) 
1 in 10,000  This is a genetic condition where the baby cannot 
break down certain fats to make energy. This can 
be problematic when a baby has an illness and 
can be fatal when a baby has an infection and 
cannot eat food as the baby cannot burn stored 
fat. 
 22 
In 2011/12, the Scottish Newborn Screening Laboratory performed newborn blood spot tests for 
58,686 babies. Of the 58,686 screens, there were 8 presumptive positive results for PKU, 41 for 
CHT, 32 for CF, 5 for MCADD and 9 for SCD and other haemoglobinopathies. These 94 
presumptive positive cases were given referral for diagnostic testing. In the same year, 
screening was declined by parent/guardians in 21 cases for PKU, CHT and MCADD with 23 
screens declined for CF and 27 screens declined for SCD (National Services Division, 2012f). 
Newborn Hearing Screening 
The Universal Newborn Hearing Screening Programme is a hearing test for newborn babies. It 
is usually performed before a baby leaves hospital. Hearing loss in one or both ears affects 
around 1 in 1,000 babies and most of these babies are born into families with no family history 
of hearing loss. Results are usually given at the time of the test (National Services Division, 
2012g). 
Newborn Physical Examination 
In England, the NHS Newborn and Infant Physical Examination (NIPE) Screening Programme, 
offers parent/guardians the opportunity to have a physical head to toe examination of the baby 
to check for any abnormalities at 72 hours after birth and then again at 6-8 weeks of age 
(National Screening Committee, 2012c). It includes a detailed examination of the baby‟s eyes, 
heart, hips and testes in boys. In Scotland, newborn and infant physical examination is not a 
national screening programme but it is routinely carried out throughout NHS Scotland (National 
Screening Committee, 2012d). 
ADULT SCREENING 
There are five adult screening programmes in Scotland. These are for bowel cancer, breast 
cancer, cervical cancer, diabetic retinopathy and abdominal aortic aneurysm.  
Bowel Cancer Screening 
Bowel cancer (sometimes known as colorectal cancer) is the third most common cancer in 
Scotland after lung and breast cancer and is the second most common cancer in men in 
Scotland. It is a major public health concern as Scotland has a higher rate of bowel cancer than 
any other Western country (ISD Scotland, 2012a). The Scottish Bowel Screening Programme 
offers a bowel screen to everyone in Scotland, every 2 years, between the ages of 50 and 74. In 
England and Wales, the equivalent programmes are offered to those aged 60 to 74 and the 
Northern Ireland equivalent is offered to those aged 60 to 69 (National Screening Committee, 
2012e). Younger people who have certain genetic conditions or who have a family history of 
bowel cancer may be offered screening at an earlier age. 
Screening for bowel cancer looks for early signs of cancer in otherwise healthy people who 
have no symptoms of the disease. Screening for bowel cancer is relatively straightforward and 
requires only small samples of bowel motions (faecal occult blood (FOB) testing). These can be 
taken at home using the kit sent by the NHS board and can be posted back free of charge. For 
every 1,000 people that take the FOB test, around 20 will have an abnormal result. They are 
offered a colonoscopy for diagnosis and of these people, around 2 will be diagnosed with bowel 
cancer (Cancer Research UK, 2012). Regular bowel screening has been shown to reduce the 
risk of dying from bowel cancer by 16% (Cancer Research UK, 2012).  
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In Scotland, uptake of bowel cancer screening from those eligible over the 2 year period from 
November 2008 – October 2010 was 53.7%. Females are more likely than males to uptake 
bowel cancer screening with 57.2% of eligible females taking the test compared to only 50.0% 
of males during the same two-year period (ISD Scotland, 2012c). Uptake of bowel cancer 
screening is also affected by social factors. Only 38.7% of eligible males living in the most 
deprived areas in Scotland took part in the screening programme (ISD Scotland, 2012c). Of 
everyone screened, 2.3% were given a positive result and were referred for further diagnostic 
testing. The screen positive rate varies geographically across Scotland with the highest bowel 
cancer screen positive rates being from NHS Lanarkshire and NHS Greater Glasgow & Clyde. 
The lowest screen positive rates are in catchment areas of NHS Fife, NHS Grampian, NHS 
Tayside and NHS Dumfries and Galloway. The screening programme detected twice as many 
cancers in men than it did in women. Of the people who were screen positive, diagnostic testing 
confirmed that 8% of the men and 6.4% of the women had a form of bowel cancer (ISD 
Scotland, 2012c). Bowel screening can also detect small growths in the bowel called polyps, 
which can have the potential of becoming cancerous. 
Breast Cancer Screening 
Breast cancer is the most common cancer diagnosis for women in Scotland, although it is the 
second most common cause of cancer death in women (after lung cancer). In Scotland, over 
4000 women are diagnosed and around 1,000 women and 10 men die of breast cancer each 
year (Breast Cancer Care, 2011). 
The Scottish Breast Screening Programme is provided by 6 breast screening centres in 
Scotland (Aberdeen, Dundee, Edinburgh, Glasgow, Inverness and Irvine) supported by 19 
mobile units for remote areas (National Services Division, 2011). Currently, around 80% of the 
screening takes place on the mobile units (National Services Division, 2011). Women aged 
between 50 and 70 are invited for a mammogram every 3 years. Women over the age of 70 are 
not routinely invited for screening, but can request a screen. Younger women with a family 
history of breast cancer may also be invited for regular screening.  
Figures for 2010-11 show that the Scottish Breast Screening Programme detected around 1,700 
cases of breast cancer and uptake of screening for those eligible is around 74.9% (ISD 
Scotland, 2012d). In 2010-11, 9.3 cancers were detected per 1000 screens performed. In total, 
the screen identified around 1,700 cases of breast cancer (ISD Scotland, 2012d). 
Cervical Cancer Screening 
Cervical Cancer is the most common form of cancer for women under the age of 35 in Scotland 
(NHS Greater Glasgow & Clyde, 2011). The Scottish Cervical Screening Programme offers 
screening (pap smear test) to all women in Scotland between the ages of 20 and 60 every 3 
years. The smear test aims to detect abnormal changes in a woman‟s cervix which if left 
untreated could develop into cervical cancer. It is estimated that cervical screening saves 
around 5,000 lives in the UK each year and prevents 8 out of 10 cervical cancers from 
developing in the first place (Health Protection Scotland, 2012).  
In 2010/11, uptake of cervical cancer screening within the past 3.5 years was 73.6% of eligible 
women across Scotland. Of the 379,355 tests processed in 2010/11, 97% were of a satisfactory 
quality. Of satisfactory results, 90.8% were deemed low-risk (negative result) with the remainder 
referred for further diagnostic testing (ISD Scotland, 2012e). 
The human papillomavirus (HPV) can cause cervical cancer. It is a very common virus and can 
spread via sexual intercourse. Because it is so common, most people will be infected by HPV at 
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some point of their life (Immunisation Scotland, 2012). There are different types of HPV and it is 
two special types of HPV that cause around 70% of cervical cancers (Immunisation Scotland, 
2012). The HPV vaccination was introduced in 2008 for girls aged 12-13 years (S2 High School 
girls). Girls need three doses over a period of six months to provide the best protection. As of 
September 2012, the vaccination will protect against the two most dangerous HPV strains that 
cause around 70% of cervical cancers, whilst providing protection against another two types of 
HPV and genital warts. However, the vaccination does not provide protection against all types of 
HPV and therefore regular screening is important (Immunisation Scotland, 2012).  
The most recent figures show that in 2010-11, uptake of HPV vaccination for girls in S2 at High 
School was 91.8% for the first dose, 90.2% for the second dose and 81.0% for the third dose 
(ISD Scotland, 2012f). Data collected from 2008 show that a number of girls complete the 
immunisation programme after the end of the school year in which they were offered the 
vaccine. Therefore, uptake rate is likely to be higher than published as some girls will not get 
their third dose until 2012-13 when they are in S3 at school (ISD Scotland, 2012f). Updated 
figures are to be published by Information Services Division in September 2012. 
Diabetic Retinopathy Screening 
There are approximately 150,000 people in Scotland with diabetes and around 5-10% of 
diabetics have a sight-threatening retinopathy (Facey et al., 2002). Retinopathy is a condition 
that can cause severe damage to the eye and can result in blindness. Diabetic retinopathy is the 
biggest single cause of blindness and visual impairment in Scotland amongst people of working 
age (Facey et al., 2002). The rising prevalence of diabetes means that it is likely to remain a 
major health and economic problem in Scotland. If diabetic retinopathy is detected and treated 
early, damage can be minimised (National Services Division, 2012h). The Diabetic Retinopathy 
Screening Programme offers screening to everyone over the age of 12 with diabetes. They are 
invited for an eye screen once a year. In 2010-11, uptake of diabetic retinopathy screening from 
those eligible was 84.8%, despite a 4% increase from the previous year in the number of 
diabetics in Scotland aged 12 and over (NHS Scotland, 2011). Of the 238,383 people screened 
in 2010-11, 3.9% were referred to ophthalmology for further examinations (NHS Scotland, 2011) 
Abdominal Aortic Aneurysm (AAA) Screening 
In July 2012, the Scottish Government announced its intention to roll out an AAA screening 
programme by 2013 for all men aged 65. An AAA is an enlarged part of the aorta that is in the 
abdomen. It usually has no symptoms unless it bursts, in which case it can be fatal. AAA is very 
common in Scotland with around 284 men aged 65 or older dying from AAA each year, with 
around 60% of these deaths preventable by screening (Scottish Government, 2012b). 
Screening will only be offered to men age 65 as 95% of ruptures occur in this group (Scottish 
Government, 2012b). The screening will use ultrasound to measure the size of the aorta. It is 
estimated that once the new screening programme is fully established it will prevent around 170 
deaths by AAA each year (Scottish Government, 2012b). The aim of this screening programme 
is to: 
 Reduce the mortality rate associated with the risk of aneurysm rupture in men aged 65 
years and older; and 
 Shift the balance of care from reactive emergency management of rupture to elective 
management through early diagnosis (Healthcare Improvement Scotland, 2011). 
Screening can identify men with AAA and for those with a large AAA, surgery or lifestyle 
changes can reduce the chance of the AAA rupturing. Those with a small or medium AAA will 
be called back for regular surveillance.  
  
APPENDIX 1: PROFESSIONAL GENETICS ASSOCIATIONS  
Organisation Aims 
British Society for Human Genetics (BSHG) 
 
The BSHG is the independent umbrella society for 
UK professional organisations for human genetics.  
Constituent organisations of BSHG are the ACGS, 
AGNC, CGC, SGPPH and the CGG (all described 
below). 
BSHG aims to: 
 Advance the science of human genetics; 
 Promote study and research into human genetics as it relates to health and 
disease; 
 Promote public awareness of human genetics as it relates to health and 
disease; 
 Support, guide and inform the professions contributing to applications of 
genetics in the health care systems of the UK; 
 Offer informed opinion on issues of public interest in relation to genetics; 
 Co-ordinate and assist as appropriate the activities of the Constituent Groups 
(BSHG, 2012). 
 
Association of Clinical Scientists (ACS) 
 
The ACS is an association for clinical scientists 
and trainee clinical scientists throughout the UK. 
The main role of the ACS is to assess trainees as 
a preliminary to registration with the HPC. 
 
 
 
 
 
 
  
ACS aims to: 
 Promote, advance and encourage the study and practice of the application of 
science in the prevention, diagnosis and control of illness, disease and 
disability; 
 Establish, uphold and improve the standards of qualification, training, 
competence and conduct of Clinical Scientists in the United Kingdom; 
 Work with official bodies including Health Professions Council (HPC) on 
matters relating to the above; 
 Liaise with relevant professional bodies to set standards for training and 
training centres to include availability of appropriate resources, regular 
assessment, pastoral care and mechanisms for addressing students training 
issues (ACS, 2009).  
 
Association for Clinical Genetic Science 
(ACGS) 
 
The ACGS is a new professional body that is in the 
ACGS aims to: 
 Promote and advance the application and practice of clinical genetic science 
such that the discipline best serves the needs of patients and their families; 
 Collaborate with other organisations with similar objectives to the Association, 
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process of being firmly established. It is being 
formed as a result of a merger between the 
Association for Clinical Cytogenetics (ACC) and 
the Clinical Molecular Genetics Society (CMGS). 
This new professional body has been formed 
following the recognition that as genetics and 
genetic technology is a rapidly advancing field, the 
specialities of molecular genetics and cytogenetics 
are moving ever closer together (ACGS, 2012a). 
The ACC and the CMGS are in the process of 
being legally dissolved whilst the ACGS appoints a 
new chair and writes a constitution. 
both within the United Kingdom and elsewhere, to advance practice; 
 Develop and publish professional standards and national best practice with 
regard to clinical genetic science; 
 Promote research, development and innovation in clinical genetic science and 
genetic testing and facilitate translation into practice to benefit patients and 
their families; 
 Promote public awareness of clinical genetic science as it relates to health and 
disease; 
 Provide informed opinion to Government and other external bodies on issues 
relating to the application and practice of clinical genetic science; 
 Actively promote appropriate training, education and continuing professional 
development for members of the Association;  
 Provide a unified voice on issues that concern the Association and its 
members; 
 Maintain the financial viability of the Association in order to support these 
objectives (ACGS, 2012b). 
 
Association of Genetic Nurses and 
Counsellors (AGNC) 
 
AGNC is the society that represents genetic 
nurses, counsellors, associates and other non-
medical staff working within clinical genetics 
whose work involves contact with families or 
individuals affected by or at risk of a genetic 
condition. 
 
AGNC aims to: 
 Provide support for professionals working in the field; 
 Provide forums for education and scientific meetings; 
 Represent the views of the profession; 
 Prescribe good standards of clinical practice; 
 Liaise and collaborate with other clinical and scientific colleagues in the field; 
 Provide channels of communication within the profession (AGNC, 2012). 
 
Clinical Genetics Society (CGS) 
 
The CGS is the society for medically qualified 
doctors who specialise in clinical genetics and 
other professionals involved in the care of 
individuals and families with genetic conditions. 
CGS aim to: 
 Advance and promote the science and practice of clinical genetics; 
 Bring together workers who have a common interest in clinical genetics; 
 Understand, prevent, cure and alleviate conditions with a genetic aetiology; 
 Publish and disseminate reports, statements, and research findings  
 Promote and facilitate education for the genetics community, other health care 
professionals, those outwith the profession, and the wider public; 
 Encourage high standards of training for professionals within clinical genetics; 
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 Facilitate research into basic human genetics and genetic disorders;  
 Maintain excellent links with patient groups; 
 Continue constructive dialogue with government and other politicians on 
genetics-related issues (CGS, 2012). 
 
Society for Genomics, Policy and Population 
Health (SGPPH) 
 
SGPPH is a forum for those with an interest in 
genetics and molecular science and its impact on 
health. Its membership includes lawyers, 
philosophers, social scientists, public health 
professionals, policy makers, geneticists and 
molecular scientists.  
 
SGPPH aims to discuss and raise awareness of the policy, ethical, legal and social 
issues raised by genomic science and technologies (SGPPH, 2012). 
Cancer Genetics Group (CGG) 
 
Membership of CGG is open to those with an 
interest in hereditary cancers. 
 
CGG aims to improve the quality of care of patients and their families with any 
condition resulting in hereditary tumours. 
 
  
APPENDIX 2: KEY SUPPORT ORGANISATIONS FOR WOMEN WITH 
‘HIGH RISK’ PREGNANCIES 
 
Organisation Support available 
Antenatal results and choices 
(ARC) 
Provides support and information to expectant and 
bereaved parents throughout and after the antenatal 
screening and testing process. 
 
Contact a Family Scotland Provides information, support and advice to parents and 
carers of children with any special need or disability. 
Campaigns to improve the circumstances of families with 
disabled children and for inclusiveness. 
 
Down Syndrome Scotland Provides information, services and support people with 
Down syndrome, their families and carers.  
 
Positively Women Offers peer support, advice, information and advocacy for 
HIV positive women and provides special support for HIV 
positive women who are pregnant. 
 
Scottish Spina Bifida 
Association 
This is an organisation that provides a support service to 
parents of children with spina bifida and related conditions. 
It aims to empower those affected to make informed choices 
and decisions.  
 
Sickle Cell Society Provides information, counselling and care for people with 
sickle cell disorders and their families. 
 
SOFT UK Helps those affected by Edward‟s and Patau syndrome, 
chromosomal abnormalities and related disorders through 
prenatal diagnosis, termination of pregnancy / birth of the 
baby, caring for the baby and bereavement. 
 
UK Thalassaemia Society Provides information, education and research to those 
affected by, or working with thalassaemia.  
 
Waverley Care Provides support to people living with HIV and Hepatitis C, 
and to their partners, families and carers. They also aim to 
raise awareness of these conditions and their prevention. 
 
Healthtalkonline Provides video interviews and descriptions of people‟s 
experiences of health procedures, tests and conditions. 
Includes experiences of pregnancy screening, diagnostic 
testing, termination of pregnancy following a diagnosis of 
fetal abnormality and experiences of living with different 
conditions. 
 
Health in my language Website that provides information on a wide range of health 
topics and health services in Scotland in different 
languages. 
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APPENDIX 3: KEY SUPPORT ORGANISATIONS FOR NEWBORN 
SCREEN POSITIVES 
 
 
Organisation Support available 
The National Society for 
Phenylketonuria (NSPKU) 
NSPKU provides help and support to people with PKU, their 
families and carers and campaigns. 
 
Cystic Fibrosis Trust Provide practical support and advice to people with Cystic 
Fibrosis and their families. Support individuals to ensure 
they have the best level of care. 
 
Sickle Cell Society Provides information, counselling and care for people with 
sickle cell disorders and their families. 
 
British Thyroid Foundation Support people with thyroid disorders and helping their 
families and people around them to understand the 
condition. 
 
Children Living With Inherited 
Metabolic Diseases (CLIMB) 
Provide confidential support, advice and information about 
MCADD and other metabolic disorders and promote 
awareness of them. 
 
National Deaf Children’s 
Society (NDCS) 
Dedicated to removing barriers for deaf children and young 
people. Provide a support network to new parents and 
carers of deaf children. 
 
Contact a Family Scotland Provides information, support and advice to parents and 
carers of children with any special need or disability. 
Campaigns to improve the circumstances of families with 
disabled children and for inclusiveness. 
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APPENDIX 4: KEY SUPPORT ORGANISATIONS FOR ADULT 
SCREEN POSITIVES 
 
 
Organisation Support available 
Bowel Cancer UK Provide practical support and advice about bowel cancer, 
raise awareness about the disease and campaign for best 
treatment and care. 
 
Breast Cancer Care Provide information and support for anyone affected by 
breast cancer. 
 
Jo’s Cervical Cancer Trust Provide information about cervical cancer and support and 
friendship to women of all ages affected by cervical cancer. 
 
Macmillan Cancer Support Provide practical, medical and financial support to people 
affected by cancer and push for better cancer care. 
 
Diabetes UK Cares for, connects with and campaigns on behalf of all 
people affected and at risk of diabetes in the UK. 
 
Circulation Foundation Promote research into causes, treatment and prevention of 
vascular disease in the UK. Provide information and support 
for patients and families affected by vascular disease, 
including abnormal aortic aneurysms. 
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